{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:14:25Z","timestamp":1792120465123,"version":"4.4.0"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Nasal decolonization has a proven effect on the prevention of severe\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            infections and the control of methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MRSA). However, rising rates of resistance to antibiotics highlight the need for new substances for nasal decolonization. LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis. This mechanism of action is not associated with cross-resistance and has a low propensity for development of resistance. In the present study, persistent nasal MRSA and methicillin-sensitive\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            (MSSA) carriers were treated for 3 days with vehicle or with 1%, 2%, or 5% LTX-109. A significant effect on nasal decolonization was observed already after 2 days of LTX-109 treatment in subjects treated with 2% or 5% LTX-109 compared to vehicle (\n            <jats:italic>P<\/jats:italic>\n            \u2264 0.0012 by Dunnett\u2032s test). No safety issues were noted during the 9-week follow-up period. Minimal reversible epithelial lesions were observed in the nasal cavity. The systemic exposure was very low, with a maximum concentration of drug in plasma (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) at 1 to 2 h postdosing (3.72 to 11.7 ng\/ml). One week after treatment initiation, LTX-109 was not detectable in any subject. Intranasal treatment of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            with LTX-109 is safe and reduces the bacterial load already after a single day of treatment. Hence, LTX-109 has potential as a new and effective antimicrobial agent with a low propensity of resistance development that can prevent infections by MSSA\/MRSA during hospitalization. (This study has been registered at\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n            under registration no. NCT01158235.)\n          <\/jats:p>","DOI":"10.1128\/aac.03513-14","type":"journal-article","created":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T02:43:11Z","timestamp":1413859391000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":99,"title":["LTX-109 Is a Novel Agent for Nasal Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus"],"prefix":"10.1128","volume":"59","author":[{"given":"Anna C.","family":"Nilsson","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Infectious Diseases Research Unit, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Janson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical Microbiology Unit, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda","family":"Wold","sequence":"additional","affiliation":[{"name":"Lytix Biopharma AS, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Fugelli","sequence":"additional","affiliation":[{"name":"Lytix Biopharma AS, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Infectious Diseases Research Unit, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"H\u00e5kang\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Infectious Diseases Research Unit, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Infectious Diseases Research Unit, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenche Marie","family":"Olsen","sequence":"additional","affiliation":[{"name":"Lytix Biopharma AS, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70295-4"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5153.658"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.1.216"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003069"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2007.08.010"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808939"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-4012-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp159"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/598187"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12028"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/500625"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006216.pub2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03137.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01834-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986707779313435"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi7019904"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm701600a"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm200450h"},{"key":"e_1_3_2_20_2","volume-title":"Abstr 51st Intersci Conf Antimicob Agents Chemother","author":"Mortensen B","year":"2011","unstructured":"Mortensen B, Fugelli A, Olsen WM. 2011. Evaluation of the preclinical safety and tolerability profile of LTX-109 a novel antimicrobial drug. Abstr 51st Intersci Conf Antimicob Agents Chemother, Boston, MA."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000119707"},{"key":"e_1_3_2_22_2","volume-title":"Abstr 49th Intersci Conf Antimicrob Agents Chemother","author":"Morrissey I","year":"2009","unstructured":"Morrissey I, Fugelli A, Olsen WM, Mortensen B, Stensen W, Svendsen JS. 2009. The activity of LTX-109 against a range of recent gram positive and gram negative clinical isolates. Abstr 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, CA."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00194-12"},{"key":"e_1_3_2_24_2","volume-title":"Abstr 52nd Intersci Conf Antimicrob Agents Chemother","author":"Wold H","year":"2013","unstructured":"Wold H, Mortensen B, Fugelli A, Olsen W. 2013. LTX-109\u2014a rapidly bactericidal antimicrobial drug highly effective on biofilms and CA-MRSA. Abstr 52nd Intersci Conf Antimicrob Agents Chemother, Denver, CO."},{"key":"e_1_3_2_25_2","volume-title":"Abstr 19th Eur Congr Clin Microbiol Infect Dis","author":"Morrisey I","year":"2009","unstructured":"Morrisey I, Fugelli A, Stensen W, Svendsen JS. 2009. Studies on resistance development to LTX-109, a novel amtimicrobial peptide, abstr P1082. Abstr 19th Eur Congr Clin Microbiol Infect Dis, Helsinki, Finland."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2011.562530"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.6.2429-2433.2000"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.11.3556-3563.1999"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5442-5448.2003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/501795"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.2000.0755"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/647237"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430110089009"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0195941700003465"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440102"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726362"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.3.466"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207290"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-12"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2013.02.005"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/520663"},{"key":"e_1_3_2_43_2","volume-title":"Abstr 51st Intersci Conf Antimicrob Agents Chemother","author":"Olsen WM","year":"2011","unstructured":"Olsen WM, Mortensen B, Khan J, Rahman M, Svendsen J, Fugelli A. 2011. LTX-109 is active against CA-MRSA (USA300) and S. pyogenes in a mouse skin infection model. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1312.070629"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/345955"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/502522"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03513-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03513-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:56:13Z","timestamp":1645484173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03513-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1128\/AAC.03513-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03513-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"2014-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}